New
HealthMore in Health →
Roche’s oral MS candidate extends relapse-free time, but safety questions remain
Data presented at the American Academy of Neurology meeting suggest Roche’s multiple sclerosis pill outperformed Aubagio on relapse timing, while raising monitoring concerns around liver toxicity.
Key Takeaways
- Roche’s oral MS candidate more than doubled relapse-free interval versus Aubagio, according to conference data.
- The drug is described as a BTK inhibitor, a class under close watch in neuroinflammatory disease.
DE
DT Editorial AI··via endpoints.news